



Company Announcement no. 5/2013

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, 6 March 2013

**Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants and announces trading in the company's shares by executives**

Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by 1,250,000 new shares with a nominal value of DKK 0.10 each corresponding to nominal DKK 125,000 as a consequence of the exercise of warrants by members of executive management granted under the company's warrant program.

The subscription price for the new shares is DKK 0.35 per share of nominal DKK 0.10 and proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 437,500.

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares gives rights to dividend and other rights from the time of the warrant holder's exercise notice.

The new shares will be listed on NASDAQ OMX Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 166,057,242.60 divided into shares of DKK 0.10 each.

The content of this announcement has no impact on the company's financial outlook for 2013.

**For more information, please contact:**

Veloxis Pharmaceuticals A/S

Bill Polvino  
President & CEO  
Mobile: +1 917 647 9107  
Email: wjp@veloxis.com

Johnny Stilou  
EVP, Chief Financial Officer  
Mobile: +45 21 227 227  
Email: jst@veloxis.com

For further information, please visit [www.veloxis.com](http://www.veloxis.com).

**About Veloxis Pharmaceuticals**

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.